The prognosis for children with the most common childhood malignancy, acute lymphoblastic leukemia (ALL), has improved dramatically. However, the burden of therapy can be substantial, with long-term side-effects, and certain subgroups continue to have a poor outcome.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed each year in the United States and Western Europe. Fifty years ago, very few children with ALL survived. Today the 5-year survival rate exceeds 90% [1] . The remarkable survival improvements have been driven by the use of complex multiagent chemotherapy regimens, focused central nervous system (CNS) treatment, and the recognition of clinical, biological, and treatment response characteristics that identify patients at lower or higher risk of treatment failure. Despite these successes, most children with ALL who relapse will not be cured, and ALL remains a leading cause of cancer death in young persons. More recently, precision medicine approaches have been incorporat ed into small ALL subsets and large scale next generation sequencing strategies have identified additional genetic alterations and pathways for precision medicine targeting. Below we discuss new therapeutic approaches, with the goal of curing every child and teenager with ALL allowing them to lead happy, productive lives. use of the same basic 'tool kit' of chemotherapy agents. The major exception is those children with Ph þ ALL. The Ph þ or (9;22) (q34;q11) translocation fuses the chromosome 22 gene BCR to the ABL1 gene from chromosome 9 and encodes for a BCR-ABL1 fusion protein that is constitutively active tyrosine kinase, driving cell growth and promoting survival. The Ph þ is present in essentially all patients with chronic myeloid leukemia, about a quarter of adults and about 3-5% of children with ALL. Prior to the development of tyrosine kinase inhibitors (TKIs), Ph þ ALL was a very poor prognosis subset with long-term event-free survival (EFS; survival without relapse or death from toxicity) rates of only about 35%, despite widespread use of allogeneic hematopoietic stem cell transplantation (HSCT) [2] .
Imatinib was the first BCR-ABL1-specific TKI and showed remarkable activity in patients with chronic myeloid leukemia. Studies then showed that the addition of imatinib to intensive chemotherapy in children with Ph þ ALL substantially improved outcome [3] . In the original Children's Oncology group (COG) AALL0031 trial, the 7-year EFS rate for children with Ph þ ALL treated with this strategy was 72%, as compared with 27% for similar children treated in the pre-TKI era [4] .
This approach is now termed precision cancer medicine, where targeted agents are directed against underlying molecular defects that drive the survival of cancer cells. In pediatric ALL, the Therapeutically Applicable Research to Generate Effective Therapies Project (TARGET; https://ocg.cancer.gov/programs/ target) has uncovered many previously unknown somatic genetic abnormalities critical for the growth of leukemia cells. One of the most important subtypes is called 'Philadelphia chromosome-like' (Ph-like) or BCR-ABL1-like ALL because these cases have gene expression profiles that resemble those of Phþ ALL, but lack BCR-ABL1 fusion [5, 6] .
The Ph-like ALL subtype, which accounts for about 15% of pediatric ALL cases and 25% of ALL cases arising in older teenagers and young adults, is associated with a very poor outcome, reminiscent of that of Ph þ ALL in the pre-TKI era. A number of studies have now unraveled the complex genomics of Ph-like ALL and shown that there are several subgroups that comprise this disorder. Importantly, several subgroups are defined by genetic lesions that are targetable by Food and Drug Administration (FDA)-approved available TKIs [7 && ]. One subgroup which accounts for about 25% of Ph-like ALL cases, is defined by translocations and genomic rearrangements that create fusion genes analogous to BCR-ABL1 involving one of four tyrosine kinase genes, ABL1 itself, its homologue ABL2, CSF1R, or PDGFRB. These kinases are fused in-frame to a wide variety of partner genes creating constitutively active tyrosine kinases such as BCR-ABL1, and all are sensitive to imatinib and related ABL class TKIs, just like BCR-ABL1. There are a variety of anecdotal reports showing that children and adults with Ph-like ALL respond remarkably to imatinib or dasatinib. The COG is developing a clinical trial that will open in 2016 and will treat children with Ph-like ALL and ABL class fusions with chemotherapy plus dasatinib.
A second major class of Ph-like ALL has driver genetic lesions that affect the JAK (Janus kinase) signaling pathway, which can be targeted by ruxolitinib. The COG is developing a second trial, also expected to open to accrual in 2016, to add ruxolitinib to chemotherapy in this subtype of Ph-like ALL. It is hoped that next generation sequencing studies will define other subtypes of ALL and other pediatric cancers that can be treated with analogous precision medicine approaches.
Improved prevention of relapse and treatment of relapsed acute lymphoblastic leukemia
The outcome for children who relapse, especially those who relapse in the bone marrow, remains dismal, making relapsed ALL the fifth most common childhood malignancy and one of the most frequent causes of cancer-related mortality in children [8] . In spite of many attempts to intensify therapy, including using HSCT, the outcome for relapsed ALL has not improved over the last 2
KEY POINTS
Newly discovered genetic alterations that drive highrisk Ph-like ALL can now be targeted with TKIs and JAK inhibitors leading to clinical trials for this particularly high-risk subset.
Novel immunotherapeutic approaches using bispecific T-cell engager antibodies and CAR T cells offer great promise in treating relapsed ALL, a leading cause of cancer cell death in children.
The discovery of relapse-specific mutations provides an explanation for clonal evolution, drug resistance, and the possibility of designing therapy to prevent relapse.
Host genetic polymorphisms are associated with predisposition to childhood ALL, response to therapy and side-effects.
CNS irradiation can be limited to a very small subset of patients at initial diagnosis or abandoned completely, thereby reducing neuropsychological sequelae of therapy.
decades, creating an urgent need for novel approaches to prevent and treat relapse.
Currently, all patients undergo reinduction chemotherapy even those with isolated extramedullary relapse since these patients will develop systemic disease if not retreated. Those with early relapse benefit from HSCT. However, many patients fail to achieve remission, suffer a second relapse early before HSCT or may not have a suitable donor. Even those patients who do undergo HSCT, remain at significant risk for second relapse. Current strategies use early response to reinduction therapy to determine which of the children with late relapse should undergo HSCT and which should be treated with chemotherapy alone [8] .
Given the poor outcome of patients retreated with conventional agents, with or without HSCT, new approaches are mandatory. Two new immunologically based therapies offer great promise. Many studies have shown that cytotoxic T cells usually present within tumors play a critical role in tumor surveillance yet cancer cells develop mechanisms to evade immune attack. Blinatumomab is a bispecific T-cell engager single chain antibody with specificity for T cells (CD3) and leukemia cells (CD19) [9, 10] . As such it acts to bring T cells in close proximity to the malignant B cells, initiating an immune synapse and subsequent cytolysis (Fig. 1) . Blinatumomab has shown impressive responses in patients with B-cell malignancies that resulted in the FDA granting breakthrough status in December 2014 [11] [12] [13] . The drug is given by continuous infusion for 28-day cycles and in a phase I/II trial in children with relapsed refractory disease 32% of patients achieved a complete response [14] . Common side-effects included fever, nausea, and headache. A rare but very serious side-effect is cytokine release syndro me (CRS) initiated by a vigorous immune response. Such patients can develop hypotension, severe capillary leak, and multisystem organ failure. Blinatumomab is at present being evaluated when delivered with conventional agents in a COG trial for relapsed ALL.
Another particularly exciting approach is the use of CD19-directed chimeric antigen receptor (CAR) T cells [15 && ] (Fig. 1) . CARs contain an extracellular tumor recognition domain, in this case a single chain monoclonal CD19 antibody fragment, linked to an intracellular T cell activation module. A variety of gene transfer techniques can be used to engineer the patient's own-harvested T cells to express this protein, and the autologous T cells are then reinfused back into the patient. Early CAR T cells relied on an intracellular CD3 signaling domain but second and third generation versions have added one and two costimulatory domains. These changes led to greater stimulation and persistence of engineered T cells. Clinical trials of CD19-CAR T cells have shown striking activity in both adult and pediatric ALL with complete response rates from 70 to 90% in relapsed/refractory cases [16 && ,17] . Although such patients have proceeded to HSCT, many have achieved sustained responses with CAR T cells alone. Cytokine release syndrome is much more common (and severe) with CAR T cells and represents dramatic T cell proliferation and cytokine production. It is more likely to occur in patients with high-tumor burden and most patients require intensive care level support. The impact of CRS has been reduced significantly by the use of the interleukin-6 receptor inhibitor tocilizumab without reducing the efficacy of CAR T cells [18] . Although these results are impressive, challenges remain in terms of optimizing CAR T cell therapy. Relapse after CAR T cells has been associated with the emergence of both CD19-positive and negative leukemia cells. In the former case, efforts to improve the persistence of CAR T cells are needed. In the latter case, the use of 'tandem' CAR T cells targeted to additional leukemia cell surface molecules may prevent the emergence of such escape variants.
Until recently, the underlying biological mechanisms that lead to drug resistance and relapse were unknown. High-throughput genomic analysis of diagnosis/relapse-paired samples showed that the relapse clone is almost always related to the clone at initial diagnosis. In fact, both the leukemia population at diagnosis and relapse is made up of many related subclones containing unique changes but sharing common lesions [19 & ]. The relapse is usually generated from a progenitor clone or emerges from expansion of a minor subclone at diagnosis through the evolutionary pressure of chemotherapy (Fig. 2 ) [20, 21] . Specific alterations are associated with panresistance to all conventional agents or may be associated with resistance to a single class [22] . For example, activation of both the Wnt and mitogen-activated protein kinase pathways (MAPK) is commonly observed at relapse and is associated with resistance to all agents used in therapy [23, 24] . RAS mutations in part drive MAPK activation and targeted agents are available that are attractive candidates for novel therapy [24, 25] . The most common relapse-specific mutations cluster in the NT5C2 gene that encodes a 5' nucleotidase [26, 27] . These FIGURE 2. Clonal evolution of relapse, top to bottom. In many cases, the leukemia at relapse emerges from a small clone at diagnosis. Leukemia cells at diagnosis may acquire additional genetic defects that result in therapy resistance. About half of all relapses appear to result from the expansion of an ancestral clone. Rarely relapses are the result of a secondary cancer unrelated to the initial diagnosis and possibly caused by the mutagenic effects of therapy. Adapted from [20, 21] .
mutations activate the enzyme to block the action of purine analogues [6-mercpatopurine (6-MP) and 6-thioguanine (6-TG)] by preventing conversion of the pro-drug into the active products. 6-MP is the cornerstone of maintenance therapy. Similarly, recently mutations have been noted in another enzyme, PRPS1, that also blocks the pathway need ed for pro-drug activation of purine analogues, although it does so through an alternative mechanism and inhibitors of the de novo purine biosynthetic pathway may overcome resistance induced by PRPS1 mutations [28] . In both cases these mutations are observed in patients who relapse early and carry the worst prognosis
Understanding host differences in treatment response and toxicity
The human genome contains 3.2 billion base pairs and whereas the great majority of humans are >99% identical to one another, subtle variation does exist. The majority of these differences are single base substitutions called polymorphisms (SNPs). In addition to SNPs, small insertions/deletions ('indels') or large structural variations differ from one individual to the next. These host or germline differences have been shown to account for disease susceptibility, response to therapy, predisposition to side-effects and thus may account for differences in outcome between patients with the same diagnosis. Advances in high-throughput genetic techniques have made it possible to scan genomes for differences that might be associated with incidence and outcome. Familial cases of ALL are quite rare but germline TP53 mutations, characteristic of the Li-Fraumeni syndrome, are associated with ALL and 50% of patients with low-hypodiploid ALL carry germline TP53 mutations [29] . Thus such cases should be screened since a finding of a germline TP53 mutation is significant for genetic counseling of family members. Similarly, mutations in the B cell transcription factors PAX5 and ETV6 have been seen in other rare cases of familial ALL [30, 31] .
Many groups of investigators have carried out genome wide association studies on children with ALL comparing the SNPs with unaffected controls. For the most part, these studies have included children from North America and Europe. Variants in ARID5B, IKZF1, CEBPE, CDKN2A, PIP4K2A, and GATA3 have repeatedly been linked to a higher risk of developing ALL [32-34,35 && ]. The mechanistic explanation that links these genes to cancer predisposition is uncertain since many SNPs occur in noncoding introns. In some cases, these variants were enriched in subtypes of ALL (e.g., ARID5B in hyperdiploid ALL and GATA3 variants in Ph-like ALL), and . Purine analogues such as 6-MP and 6-TG are cornerstones of therapy and the active products are metabolized by the enzyme thiopurine methyltransferase (TPMT). Patients with hypofunctioning variants (especially homozygous) show much greater levels of active metabolites and therefore a greater incidence of myelosuppresion and therapy intolerance [36] [37] [38] . Similarly, a new study links a coding variant in NUDT15 with thiopurine intolerance and such variants are more common in patients of East Asian and Hispanic ancestry [39] . Some investigators recommend screening for TPMT variants so that dose can be adjusted before profound myelosuppression. In some (but not all) studies, defective TPMT variants were associated with a more rapid response to treatment and a better outcome [40] .
With the exception of TPMT, and possibly NUDT15, the SNPs associated with response and adverse effects do not explain the vast majority of the events that occur in patients. Thus, their routine integration into clinical decision making is not yet practical, but is a goal of emerging precision medicine approaches intended to maximize cure rates and avoid harmful side-effects.
Optimizing central nervous system therapy to prevent neurocognitive toxicity
The burden of ALL therapy can be substantial with approximately 40% of childhood cancer survivors experiencing a serious late effect, although fortunately data from more contemporary studies indicate that the burden may be significantly less [41] . One of the most troubling late effects is cognitive impairment because of cranial irradiation [42, 43] . Although only 2% of children have overt leukemia in the spinal fluid at diagnosis the majority of children will suffer a CNS relapse if given systemic therapy alone. Indeed the use of presymptomatic craniospinal irradiation was one of the most important advances in the treatment of ALL [44] . Radiation doses were subsequently decreased and therapy limited to the brain but many children were still left with neurocognitive impairment that manifested as impaired processing speed, global intellectual functions, and executive function. A number of randomized studies have shown that intrathecal chemoprophylaxis with methotrexate (and sometimes 'triple' therapy with cytarabine, hydrocortisone, and methotrexate) can replace cranial irradiation with no impact on long-term outcome [45] . Many of these studies intensified systemic therapy by substituting dexamethasone for prednisone (better CNS penetration), higher dose methotrexate and more frequent use of asparaginase reducing the CNS relapse rate to 6% or less [46] . Only those patients with overt CNS disease at diagnosis and certain ALL subtypes with high risk for CNS failure are given cranial irradiation, usually at lower doses (1200-1800 cGy).
Recently, the complete abandonment of cranial irradiation has been incorporated into frontline trials even for patients with overt CNS disease at diagnosis [47, 48] . Pui [47] showed that by augmenting systemic therapy, using triple IT therapy, reducing traumatic lumbar punctures (associated with contamination of the CNS with peripheral blood blasts), and using risk-stratified therapy that included minimal residual disease testing, achieved a superior 5-year EFS (93.5%) with only 2.7% of patients suffering a CNS relapse. Moreover, salvage for such patients who relapse without prior cranial irradiation is much better than those who receive cranial irradiation.
CONCLUSION
Treatment of childhood ALL is one of the major successes of modern medicine and has provided a paradigm for how cancer survival can be steadily increased through cooperative group clinical trials. New genomic discoveries and precision medicine approaches have the potential to both increase survival, and decrease short and long-term adverse events. The biggest challenge is exporting improvements in care to low and middle-income countries worldwide. In many middle-income countries, ALL survival rates are about 50%, similar to those of the late 1970s in high-income countries [49] . In lowincome countries, few children with ALL survive leading to the loss of millions of productive years of life. Our goal must be to cure all children who develop ALL, wherever they reside.
